- Home
- ACIC vs AVBP Comparison
ACIC vs AVBP Comparison
Compare ACIC & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- AVBP
- Stock Information
- Founded
- ACIC 1999
- AVBP 2021
- Country
- ACIC United States
- AVBP United States
- Employees
- ACIC N/A
- AVBP N/A
- Industry
- ACIC Property-Casualty Insurers
- AVBP
- Sector
- ACIC Finance
- AVBP
- Exchange
- ACIC Nasdaq
- AVBP NYSE
- Market Cap
- ACIC 569.6M
- AVBP 893.4M
- IPO Year
- ACIC N/A
- AVBP 2024
- Fundamental
- Price
- ACIC $10.86
- AVBP $28.01
- Analyst Decision
- ACIC Buy
- AVBP Strong Buy
- Analyst Count
- ACIC 1
- AVBP 5
- Target Price
- ACIC $15.00
- AVBP $31.40
- AVG Volume (30 Days)
- ACIC 195.2K
- AVBP 211.5K
- Earning Date
- ACIC 08-07-2024
- AVBP 11-02-2024
- Dividend Yield
- ACIC N/A
- AVBP N/A
- EPS Growth
- ACIC N/A
- AVBP N/A
- EPS
- ACIC 1.43
- AVBP N/A
- Revenue
- ACIC $261,180,000.00
- AVBP N/A
- Revenue This Year
- ACIC N/A
- AVBP N/A
- Revenue Next Year
- ACIC $13.95
- AVBP N/A
- P/E Ratio
- ACIC $7.11
- AVBP N/A
- Revenue Growth
- ACIC N/A
- AVBP N/A
- 52 Week Low
- ACIC $6.61
- AVBP $14.35
- 52 Week High
- ACIC $14.38
- AVBP $28.65
- Technical
- Relative Strength Index (RSI)
- ACIC 43.82
- AVBP N/A
- Support Level
- ACIC $10.55
- AVBP N/A
- Resistance Level
- ACIC $11.30
- AVBP N/A
- Average True Range (ATR)
- ACIC 0.39
- AVBP 0.00
- MACD
- ACIC -0.04
- AVBP 0.00
- Stochastic Oscillator
- ACIC 27.93
- AVBP 0.00
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.